Format

Send to

Choose Destination
J Obstet Gynaecol Can. 2011 Feb;33(2):153-158. doi: 10.1016/S1701-2163(16)34802-2.

The fetal safety of hydrocortisone-pramoxine (Proctofoam-HC) for the treatment of hemorrhoids in late pregnancy.

Author information

1
Motherisk Program, Hospital for Sick Children Toronto ON.
2
Sunnybrook Health Sciences Centre, Toronto ON.
3
Mount Sinai Hospital, Toronto ON.
4
North York General Hospital, Toronto ON.
5
LaSalle Clinic Montreal QC.

Erratum in

  • J Obstet Gynaecol Can. 2011 May;33(5):436.

Abstract

OBJECTIVE:

Fetal safety has never been studied for any drug used in the treatment of hemorrhoids. Proctofoam-HC is a combination of a corticosteroid and a local anaesthetic that is proven effective for the treatment of hemorrhoids. The objective of this study was to assess prospectively the fetal safety of third trimester exposure to Proctofoam-HC.

METHODS:

In a multicentre study, 204 [corrected] women exposed to Proctofoam-HC in the third trimester and a similar number of control pregnant women were followed up postnatally.

RESULTS:

When compared to controls exposure to Proctofoam-HC was not associated with any adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications.

CONCLUSION:

Proctofoam-HC is safe to use in the treatment of hemorrhoids in late pregnancy.

PMID:
21352635
DOI:
10.1016/S1701-2163(16)34802-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center